Table 3.

Multivariate analyses models for response and survival after induction chemotherapy in MDS patients experiencing HMA failure

VariableORR, %OR95% CIP
Age, y   0.28-0.78 <.01 
 <65 48 
 ≥65 34 0.47 
Cytogenetic risk   0.25-0.83 .01 
 Favorable/intermediate 47 
 Unfavorable 29 0.46 
IPSS   0.311-1.15 .12 
 Int-2 or lower 45 
 High 30 0.60 
Therapy related   0.25-1.20 .13 
 No 43 
 Yes 28 0.55 
Induction regimen   1.24-6.90 .01 
 Other (7+3 or PNA) 37 
 IDAC 64 2.91 
VariableORR, %OR95% CIP
Age, y   0.28-0.78 <.01 
 <65 48 
 ≥65 34 0.47 
Cytogenetic risk   0.25-0.83 .01 
 Favorable/intermediate 47 
 Unfavorable 29 0.46 
IPSS   0.311-1.15 .12 
 Int-2 or lower 45 
 High 30 0.60 
Therapy related   0.25-1.20 .13 
 No 43 
 Yes 28 0.55 
Induction regimen   1.24-6.90 .01 
 Other (7+3 or PNA) 37 
 IDAC 64 2.91 
VariableMedian OS, moHR95% CIP
Cytogenetic risk   0.99-2.06 .06 
 Favorable/intermediate 15.6 
 Unfavorable 8.1 1.43 
Disease status at HMA failure   0.95-2.24 .09 
 Stable 13.6 
 Progressive 10.5 1.46 
VariableMedian OS, moHR95% CIP
Cytogenetic risk   0.99-2.06 .06 
 Favorable/intermediate 15.6 
 Unfavorable 8.1 1.43 
Disease status at HMA failure   0.95-2.24 .09 
 Stable 13.6 
 Progressive 10.5 1.46 

Logistic regression multivariate analysis model for multivariate analysis of overall response and Cox model for multivariate analysis of OS after induction therapy, including all covariates with a potential outcome on response in univariate analysis (P value in univariate <.15). Cytogenetic risk was evaluated per MDS IPSS classification.

OR, odds ratio.

or Create an Account

Close Modal
Close Modal